Photocure ASA: Invitation to presentation of third quarter 2025 financial results
Photocure ASA: Invitation to presentation of third quarter 2025 financial results
Oslo, Norway, 23 October 2024: Photocure ASA (Photocure, PHO: OSE) will announce
the third quarter 2025 financial results on Wednesday 29 October 2025 at 07:00
CET and will present a live webcast at 14:00 CET the same day.
The quarterly report and presentation will be published at 07:00 CET and will be
publicly available at www.photocure.com.
The investor presentation will be streamed live and hosted by Dan Schneider, CEO
and Erik Dahl, CFO. The presentation will be held in English and questions can
be submitted throughout the event. The presentation is scheduled to conclude at
14:45 CET.
The streaming event is available through
https://channel.royalcast.com/landingpage/hegnarmedia/20251029_2/ (https://eur01.
safelinks.protection.outlook.com/?url=https%3A%2F%2Fchannel.royalcast.com%2Flandi
ngpage%2Fhegnarmedia%2F20251029_2%2F&data=05%7C02%7CTH%40photocure.no%7Cea80d9268
60246f055f908ddfa217496%7C0986794f1d6f488980bd853c0715d3c1%7C0%7C0%7C638941743798
309045%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOi
JXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=psg%2F5Daz6%2FAI8e6
yPKy8HBHCIyiUyxzZIeZ8V93idw8%3D&reserved=0)
For further information, please contact:
Photocure
Erik Dahl
CFO
Tel: +47 45055000
Email: [email protected]
Media and IR enquiries:
Geir Bjørlo
Corporate Communications (Norway) Tel: +47 91540000
Email: [email protected]
About Photocure
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.cysview.com
This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.